Morgan Stanley recommends buying shares of Fosun Pharma (02196) with a target price of 42 yuan for A shares and 33 Hong Kong dollars for H shares.

Zhixin Finances and Economics APP has learned that a recent research report released by international investment bank Morgan Stanley indicates that Fosun Pharma (600196.SH, 02196) is showing a trend of improving profitability, with the market undervaluing the value of its innovative drug pipeline. Additionally, the financial optimization brought about by the divestment of non-core assets in the first half of 2025 has led to an upgrade of the company's A-share and H-share ratings to "overweight". The target price for Fosun Pharma's A-shares has been raised to 42 RMB, and for H-shares to 33 HKD, indicating significant upside potential compared to the current stock price. This expectation is highly consistent with Fosun Pharma's recent disclosure of its performance in the first half of 2025, highlighting its dual breakthroughs in the commercialization of innovative drugs and financial resilience.